skip navigationU S P T O SealUnited States Patent and Trademark Office AOTW logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
Assignments on the Web > Patent Query
Patent Assignment Abstract of Title
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 3
Patent #:
Issue Dt:
01/22/2002
Application #:
09187789
Filing Dt:
11/06/1998
Inventors:
EMAD S. ALNEMRI, TERESA FERNANDEZ-ALNEMRI
Title:
CASPASE-14, AN APOPTOTIC PROTEASE, NUCLEIC ACIDS ENCODING AND METHODS OF USE
Assignment: 1
Reel/Frame:
009743/0248Recorded: 01/25/1999Pages: 3
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignors:
Exec Dt:
12/21/1998
Exec Dt:
12/21/1998
Assignee:
1020 LOCUST STREET
PHILADELPHIA, PENNSYLVANIA 19107
Correspondent:
SEED AND BERRY LLP
DAVID J. MAKI
701 FIFTH AVENUE
6300 COLUMBIA CENTER
SEATTLE, WA 98104-7092
Assignment: 2
Reel/Frame:
010222/0033Recorded: 09/09/1999Pages: 7
Conveyance:
CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS).
Assignor:
Exec Dt:
06/28/1999
Assignee:
EXTRAMURAL INVENTIONS OFFICE, THE, MSC 7980
6705 ROCKLEDGE DRIVE, SUITE 1040
BETHESDA, MARYLAND 20892
Correspondent:
NATIONAL INSTITUTES OF HEALTH, THE
BELEN AWETAHEGNE
6705 ROCKLEDGE DRIVE, SUITE 1040
MSC 7980
BETHESDA, MARYLAND 20892-7980
Assignment: 3
Reel/Frame:
022111/0121Recorded: 01/15/2009Pages: 2
Conveyance:
CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS).
Assignor:
Exec Dt:
06/28/1999
Assignee:
NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)
6705 ROCKLEDGE DRIVE, SUITE 310, MSC 7980
BETHESDA, MARYLAND 20892-7980
Correspondent:
DIRECTOR, DEITR
NIH, 6705 ROCKLEDGE DRIVE, SUITE 310
MSC 7980
BETHESDA, MD 20892-7980

Search Results as of: 06/03/2024 10:31 AM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified: August 25, 2017 v.2.6
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT